Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
12.39
-0.42 (-3.28%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.36 - 12.76
52 week 11.80 - 19.50
Open 12.76
Vol / Avg. 520,685.00/792,802.00
Mkt cap 1.31B
P/E     -
Div/yield     -
EPS -1.33
Shares 105.58M
Beta 0.26
Inst. own 110%
Oct 30, 2017
Q3 2017 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 25, 2017
Lexicon Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference - 4:10PM EDT - Add to calendar
Sep 14, 2017
Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
Sep 13, 2017
Lexicon Pharmaceuticals Inc to Provide Update on Sotagliflozin Program from EASD Conference Call - Webcast
Aug 15, 2017
Lexicon Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Aug 1, 2017
Q2 2017 Lexicon Pharmaceuticals Inc Earnings Release
Aug 1, 2017
Q2 2017 Lexicon Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -290.87% -169.71%
Operating margin -281.20% -164.58%
EBITD margin - -162.11%
Return on average assets -37.02% -25.09%
Return on average equity -116.74% -63.81%
Employees 168 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 52
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and Supply Operations
Age: 63
Bio & Compensation  - Reuters
Alexander A. Santini Executive Vice President, Chief Commercial Officer
Age: 58
Bio & Compensation  - Reuters
Praveen Tyle Ph.D. Executive Vice President - Research and Development
Age: 57
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 57
Bio & Compensation  - Reuters
Philippe J. Amouyal Independent Director
Age: 58
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters